The medical uses of<unk>  are the same as those of estradiol and other estrogens. Examples of indications for the medication include hormone therapy and hormonal contraception. In regard to the latter,<unk>  is available in combination with a progestin as a combined estradiol-containing oral contraceptive (with dienogest) and as a combined injectable contraceptive. Along with estradiol cypionate, estradiol undecylate, and estradiol benzoate,<unk>  is used as a form of high-dose estrogen therapy in feminizing hormone therapy for transgender women. It is also used as a form of high-dose estrogen therapy in the treatment of prostate cancer in men. Low-dose oral<unk>  (2–6 mg/day) has been used in the treatment of breast cancer in women who were previously treated with and benefited from but acquired resistance to aromatase inhibitors as well. In the United States, the approved indications of<unk>  injections include the treatment of moderate to severe hot flashes and vaginal atrophy associated with menopause in women, the treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure in women, and the palliative treatment of advanced prostate cancer in men. Elsewhere in the world, oral<unk>  is similarly approved for the treatment of symptoms associated with menopause or hypoestrogenism due to castration in women. Such symptoms may include hot flashes, outbreaks of sweat, sleep disturbances, depressive moods, irritability, headaches, and dizziness.<unk>  by intramuscular injection is usually used at a dosage of 10 to 20 mg<unk> ery 4 weeks in the treatment of menopausal symptoms and hypoestrogenism due to hypogonadism, castration, or primary ovarian failure in women. In the past, it was used at<unk> en higher doses of 10 to 40<unk> ery 1 to 4 weeks for estrogen replacement.<unk>  is usually used in the treatment of advanced prostate cancer in men at a dosage of 30 mg or more<unk> ery 1 to 2 weeks by intramuscular injection. In transgender women,<unk>  given by intramuscular injection is usually used at a dosage of 5 to 20 mg, but up to 30 to 40 mg, once<unk> ery 2 weeks.<unk>  has also been used at a dose of 10 to 40 mg by intramuscular injection to limit bleeding in women with hemorrhage due to dysfunctional uterine bleeding. Available forms<unk>  is and has been available in the form of vials and ampoules of oil solution for intramuscular injection in concentrations of 4, 5, 10, 20, and 40 mg/mL and in the form of oral tablets at doses of 0.5, 1, 2, and 4 mg per tablet. In the United States, it is specifically available in formulations of 10, 20, and 40 mg/mL in oil solution (as Delestrogen, as well as generics). Aside from<unk> , the only other injectable estrogen formulations that remain available in the United States are estradiol cypionate (5 mg/mL in oil solution) and conjugated estrogens (25 mg/vial in solution). Some or all oral<unk>  tablets are micronized, similarly to oral estradiol tablets. In addition to single-drug formulations, oral<unk>  is available in combination with the progestin dienogest as a combined oral contraceptive and intramuscular<unk>  is marketed at a concentration of 5 mg/mL in combination with the progestin hydroxyprogesterone caproate and with the progestin norethisterone enantate as combined injectable contraceptives. Intramuscular<unk>  is also marketed at a concentration of 4 mg/mL in combination with the weak androgen and neurosteroid prasterone enanthate ( enanthate) and with the androgen testosterone enantate for use in menopausal hormone therapy, but the latter formulation has been discontinued. The availability of<unk> -containing products varies throughout the world.
Estradiol valerate
Estradiol undecylate
Estradiol furoate
Estradiol dienantate
Estradiol enantate
Estradiol dipropionate
Estradiol diundecylenate
Estradiol hemisuccinate